SOPHiA GENETICS has announced a strategic collaboration with The University of Texas MD Anderson Cancer Center to accelerate the development of AI-driven precision oncology solutions. The partnership will combine SOPHiA GENETICS' advanced AI-powered analytics with MD Anderson's clinical and scientific expertise to enhance data-driven cancer care. As part of the collaboration, the two organizations will launch a series of research and development programs and co-develop an advanced next-generation sequencing oncology test. This initiative aims to translate complex multimodal data into actionable clinical insights, enabling faster and more accurate diagnosis and treatment for cancer patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NE56766) on January 07, 2026, and is solely responsible for the information contained therein.